Major Depressive Disorder: Epidemiology Report and Forecast to 2035

Explore major depressive disorder epidemiology across eight major markets, with 10-year forecasts, patient segmentation, treatment-resistant depression data, and prevalence trends to 2035.

Why Does Major Depressive Disorder Epidemiology Matter?

Major depressive disorder (MDD), also known as clinical depression, is a complex mental health condition associated with persistent changes in mood, interest, cognition, and physical functioning. While treatment options include antidepressant medications, psychotherapy, and advanced neuromodulation, some patients experience treatment-resistant depression (TRD), creating distinct considerations for treatment development and market planning.

Understanding the size, characteristics, and evolution of patient populations is essential for pharmaceutical companies and healthcare stakeholders evaluating the MDD treatment landscape. GlobalData’s Major Depressive Disorder Epidemiology Analysis provides historical data and 10-year forecasts for MDD and TRD across eight major markets (8MM), supporting patient population assessment, commercial planning, and strategic decision-making.

Key Insights in Major Depressive Disorder Epidemiology

• MDD prevalence outlook: The 12-month total prevalent cases of MDD across the 8MM are projected to increase from approximately 53.2 million in 2025 to 54.2 million in 2035.
• Treatment-resistant depression: Total prevalent cases of TRD across the 8MM are forecast to rise from approximately 10.1 million in 2025 to 10.3 million in 2035.
• Country-level differences: The US is projected to have the highest number of prevalent MDD cases in 2035, while Japan is expected to have the lowest among the eight markets.
• Patient segmentation: Assess MDD prevalence among adults aged 18 and older by sex and disease severity, including mild, moderate, and severe cases.
• Eight major markets covered: Compare epidemiological trends across the US, France, Germany, Italy, Spain, the UK, Japan, and Canada.
• Evidence-based forecasts: Explore epidemiological estimates informed by peer-reviewed articles, population-based studies, and consistent forecasting methodology across the covered markets.

Scope

What Will You Learn from This Major Depressive Disorder Epidemiology Report?

This report provides a structured view of the MDD patient population, including historical trends, risk factors, comorbidities, and future prevalence estimates.

The report helps you:

• Understand historical and projected 12-month total prevalent cases of MDD across the 8MM.
• Assess forecast changes in the patient population through 2035.
• Quantify the total prevalent population experiencing treatment-resistant depression.
• Segment adult MDD cases by age, sex, and disease severity.
• Compare epidemiological trends and patient populations across the eight major markets.
• Understand relevant risk factors, comorbidities, and population-level influences on disease prevalence.
• Use consistent cross-market forecasts to support patient population assessment and commercial planning.

Who Should Buy This Major Depressive Disorder Epidemiology Report?

This report is relevant for professionals who need reliable epidemiological insights to support pharmaceutical strategy, product development, and market planning.

• Pharmaceutical and biotechnology companies: Understand the potential patient population for existing and emerging MDD therapies.
• Commercial and business strategy teams: Use prevalence forecasts to inform market assessment, product positioning, and launch planning.
• Market access and pricing teams: Incorporate patient population estimates into pricing, access, and commercial planning assessments.
• Sales and marketing leaders: Identify relevant patient segments and assess country-level differences to inform commercial resource allocation.
• Clinical development teams: Understand patient population characteristics and the epidemiological context for MDD and TRD.
• Market research and competitive intelligence professionals: Evaluate prevalence trends and compare patient populations across major markets.
• Healthcare and life sciences investors: Gain epidemiological context to support assessments of the MDD treatment landscape.
  

  

How Companies Use This MDD Epidemiology Analysis

Businesses can use the report’s patient population estimates and forecasts to support strategic and commercial decisions.

• Quantify patient populations: Assess the current and projected number of people living with MDD and TRD across the covered markets.
• Inform product development: Use patient segmentation and prevalence trends to support therapeutic planning and product strategy.
• Support launch planning: Incorporate epidemiological forecasts into country-level launch assessments and commercial opportunity evaluations.
• Refine market segmentation: Compare patient groups by age, sex, and disease severity to help identify relevant target populations.
• Plan sales and marketing activity: Use country-specific epidemiological insights to guide market prioritization and resource allocation.
• Strengthen strategic forecasting: Incorporate historical data and 10-year projections into long-term business planning.

Reasons to Buy

Benchmark the MDD Epidemiology Landscape Across Eight Major Markets

Compare the epidemiology of major depressive disorder across the US, France, Germany, Italy, Spain, the UK, Japan, and Canada. The report includes forecasts for total prevalent MDD cases, segmented by adult age, sex, and severity, alongside estimates for treatment-resistant depression.

Consistent forecasting methodology enables meaningful comparisons across markets and supports a clearer understanding of how patient populations may evolve through 2035.

Built on GlobalData Healthcare Intelligence

GlobalData’s epidemiology analysis combines data from peer-reviewed publications and population-based studies with structured forecasting methodologies. The MDD model incorporates relevant risk factors, comorbidities, historical trends, and patient segmentation to provide a comprehensive view of the disease landscape across the eight major markets.

Act Now to Understand the Major Depressive Disorder Patient Population

As MDD and treatment-resistant depression populations evolve, robust epidemiological insights can help businesses make informed decisions about therapeutic development, market prioritization, and product launches. Use GlobalData’s Major Depressive Disorder Epidemiology Analysis to assess patient populations, compare eight major markets, and plan for projected prevalence trends through 2035.